Skip to main content

Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated Today

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

HIMS Cover Image

What Happened?

Shares of telehealth company Hims & Hers Health (NYSE: HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, and EBITDA came in a bit short, but revenue soared year over year, easily beating Wall Street's forecasts. This jump came from surging demand in the weight-loss business, which remains a key growth engine. 

That said, EBITDA slightly missed estimates, and gross margin fell from 83% to 77%, signaling rising costs to attract and serve customers. 

Looking ahead, Hims & Hers provided optimistic guidance, projecting full-year 2025 revenue and adjusted EBITDA well above analysts' expectations. 

Overall, we think this was still a solid quarter with some key areas of upside, but the worse-than-anticipated customer additions and EBITDA seem to be sending shares lower. We also note that expectations were high going into the print as the stock was up 104% year-to-date before the announcement.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Hims & Hers Health’s shares are extremely volatile and have had 73 moves greater than 5% over the last year. But moves this big are rare even for Hims & Hers Health and indicate this news significantly impacted the market’s perception of the business. 

The previous big move we wrote about was 4 days ago when the stock dropped 24% on the news that U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as Wegovy and Ozempic has ended. This could lead to lower sales for companies like Hims & Hers Health, which sell weight-loss medications through their platform.

Hims & Hers Health is up 58.2% since the beginning of the year, but at $39.86 per share, it is still trading 42% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $3,947.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.21
+4.51 (1.81%)
AAPL  272.19
+8.79 (3.34%)
AMD  276.60
-1.66 (-0.60%)
BAC  54.23
+0.72 (1.34%)
GOOG  335.87
+3.10 (0.93%)
META  683.52
+6.65 (0.98%)
MSFT  428.93
+8.67 (2.06%)
NVDA  200.75
+2.40 (1.21%)
ORCL  177.97
-0.38 (-0.21%)
TSLA  407.51
+18.62 (4.79%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.